• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Taming dendritic cells with TIM-3: another immunosuppressive strategy used by tumors.用 TIM-3 驯服树突状细胞:肿瘤使用的另一种免疫抑制策略。
Immunotherapy. 2012 Dec;4(12):1795-8. doi: 10.2217/imt.12.126.
2
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1.肿瘤浸润树突状细胞通过 TIM-3 受体与警报素 HMGB1 之间的相互作用抑制核酸介导的固有免疫反应。
Nat Immunol. 2012 Sep;13(9):832-42. doi: 10.1038/ni.2376. Epub 2012 Jul 29.
3
Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas.联合阻断 TIM-3 和 TIM-4 可增强癌症疫苗对已建立的黑色素瘤的疗效。
Cancer Immunol Immunother. 2013 Apr;62(4):629-37. doi: 10.1007/s00262-012-1371-9. Epub 2012 Nov 10.
4
A new development of FG-CC' siRNA blocking interaction of Tim-1 and Tim-4 can enhance DC vaccine against gastric cancer .FG-CC' siRNA阻断Tim-1与Tim-4相互作用的新进展可增强抗胃癌DC疫苗。
Hepatogastroenterology. 2012 Nov-Dec;59(120):2677-82. doi: 10.5754/hge11620.
5
TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance.TIM-4 糖蛋白通过自噬作用降解垂死的肿瘤细胞,导致抗原呈递减少和免疫耐受增加。
Immunity. 2013 Dec 12;39(6):1070-81. doi: 10.1016/j.immuni.2013.09.014. Epub 2013 Dec 5.
6
Tumor immunity times out: TIM-3 and HMGB1.肿瘤免疫失效:TIM-3 和 HMGB1。
Nat Immunol. 2012 Sep;13(9):808-10. doi: 10.1038/ni.2396.
7
c-Src Suppresses Dendritic Cell Antitumor Activity via T Cell Ig and Mucin Protein-3 Receptor.c-Src通过T细胞免疫球蛋白和粘蛋白3受体抑制树突状细胞的抗肿瘤活性。
J Immunol. 2016 Sep 1;197(5):1650-62. doi: 10.4049/jimmunol.1600104. Epub 2016 Jul 20.
8
Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.树突状细胞亚群的免疫调节抑制受体在上皮性膀胱癌中的作用
Eur Urol. 2017 Jun;71(6):854-857. doi: 10.1016/j.eururo.2016.10.009. Epub 2016 Oct 27.
9
Tim-1 stimulation of dendritic cells regulates the balance between effector and regulatory T cells.Tim-1 刺激树突状细胞调节效应 T 细胞和调节性 T 细胞之间的平衡。
Eur J Immunol. 2011 Jun;41(6):1539-49. doi: 10.1002/eji.201040993. Epub 2011 May 25.
10
Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.半乳糖凝集素-9可增加Tim-3阳性树突状细胞和CD8阳性T细胞,并通过半乳糖凝集素-9与Tim-3的相互作用增强抗肿瘤免疫力。
J Immunol. 2008 Dec 1;181(11):7660-9. doi: 10.4049/jimmunol.181.11.7660.

引用本文的文献

1
Potential drug targets for ovarian cancer identified through Mendelian randomization and colocalization analysis.通过孟德尔随机化和共定位分析确定的卵巢癌潜在药物靶点。
J Ovarian Res. 2025 Feb 19;18(1):32. doi: 10.1186/s13048-025-01620-7.
2
Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.胶质母细胞瘤中的免疫检查点途径:一个多样化且不断发展的领域。
Front Immunol. 2024 Sep 13;15:1424396. doi: 10.3389/fimmu.2024.1424396. eCollection 2024.
3
Development of an immunogenic cell death-related lncRNAs signature for prognostic risk assessment in gastric cancer.用于胃癌预后风险评估的免疫原性细胞死亡相关长链非编码RNA特征的开发
Transl Cancer Res. 2024 Aug 31;13(8):4420-4440. doi: 10.21037/tcr-24-344. Epub 2024 Aug 27.
4
Targeting Innate Immunity in Glioma Therapy.靶向胶质细胞瘤治疗中的固有免疫。
Int J Mol Sci. 2024 Jan 12;25(2):947. doi: 10.3390/ijms25020947.
5
T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: A Narrative Review.皮肤黑色素瘤中的T细胞免疫球蛋白和粘蛋白结构域3(TIM-3):一项叙述性综述
Cancers (Basel). 2023 Mar 10;15(6):1697. doi: 10.3390/cancers15061697.
6
Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment.肿瘤干细胞样细胞表达 midkine 促进了对 mTOR 抑制的持续作用和免疫抑制微环境。
Nat Commun. 2022 Aug 26;13(1):5018. doi: 10.1038/s41467-022-32673-7.
7
The Role of Myeloid Cells in GBM Immunosuppression.髓系细胞在 GBM 免疫抑制中的作用。
Front Immunol. 2022 May 31;13:887781. doi: 10.3389/fimmu.2022.887781. eCollection 2022.
8
Photodynamic therapy of melanoma with new, structurally similar, NIR-absorbing ruthenium (II) complexes promotes tumor growth control via distinct hallmarks of immunogenic cell death.使用新型、结构相似、吸收近红外光的钌(II)配合物对黑色素瘤进行光动力疗法,可通过免疫原性细胞死亡的不同特征促进肿瘤生长控制。
Am J Cancer Res. 2022 Jan 15;12(1):210-228. eCollection 2022.
9
Role of the Extracellular Traps in Central Nervous System.细胞外陷阱在中枢神经系统中的作用。
Front Immunol. 2021 Nov 16;12:783882. doi: 10.3389/fimmu.2021.783882. eCollection 2021.
10
Examination of the TIGIT, CD226, CD112, and CD155 Immune Checkpoint Molecules in Peripheral Blood Mononuclear Cells in Women Diagnosed with Early-Onset Preeclampsia.对诊断为早发型子痫前期的女性外周血单个核细胞中TIGIT、CD226、CD112和CD155免疫检查点分子的检测
Biomedicines. 2021 Nov 3;9(11):1608. doi: 10.3390/biomedicines9111608.

本文引用的文献

1
Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination.在疫苗接种中固有免疫和适应性免疫之间的界面进行核酸感应。
Nat Rev Immunol. 2012 Jun 22;12(7):479-91. doi: 10.1038/nri3247.
2
Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection.Tim-3 通路在丙型肝炎病毒感染期间控制调节性和效应性 T 细胞的平衡。
J Immunol. 2012 Jul 15;189(2):755-66. doi: 10.4049/jimmunol.1200162. Epub 2012 Jun 15.
3
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.Tim-3 和 PD-1 表达的上调与黑色素瘤患者肿瘤抗原特异性 CD8+ T 细胞功能障碍有关。
J Exp Med. 2010 Sep 27;207(10):2175-86. doi: 10.1084/jem.20100637. Epub 2010 Sep 6.
4
Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.树突状细胞需要全身性I型干扰素反应来成熟,并以聚肌胞苷酸作为佐剂诱导CD4+ Th1免疫。
J Exp Med. 2009 Jul 6;206(7):1589-602. doi: 10.1084/jem.20090247. Epub 2009 Jun 29.
5
Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.半乳糖凝集素-9可增加Tim-3阳性树突状细胞和CD8阳性T细胞,并通过半乳糖凝集素-9与Tim-3的相互作用增强抗肿瘤免疫力。
J Immunol. 2008 Dec 1;181(11):7660-9. doi: 10.4049/jimmunol.181.11.7660.
6
TIMs: central regulators of immune responses.T细胞免疫球蛋白黏蛋白分子:免疫反应的核心调节因子
J Exp Med. 2008 Nov 24;205(12):2699-701. doi: 10.1084/jem.20082429. Epub 2008 Nov 17.
7
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection.Tim-3表达定义了一类新型功能失调性T细胞群体,其在进展性HIV-1感染中的频率显著升高。
J Exp Med. 2008 Nov 24;205(12):2763-79. doi: 10.1084/jem.20081398. Epub 2008 Nov 10.
8
Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells.天然免疫细胞上表达的免疫受体Tim-3对组织炎症的促进作用。
Science. 2007 Nov 16;318(5853):1141-3. doi: 10.1126/science.1148536.
9
Immunosuppressive strategies that are mediated by tumor cells.由肿瘤细胞介导的免疫抑制策略。
Annu Rev Immunol. 2007;25:267-96. doi: 10.1146/annurev.immunol.25.022106.141609.
10
Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model.I型干扰素作为保护性免疫反应的天然佐剂:来自流感疫苗模型的经验教训。
J Immunol. 2002 Jul 1;169(1):375-83. doi: 10.4049/jimmunol.169.1.375.

用 TIM-3 驯服树突状细胞:肿瘤使用的另一种免疫抑制策略。

Taming dendritic cells with TIM-3: another immunosuppressive strategy used by tumors.

机构信息

Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.

出版信息

Immunotherapy. 2012 Dec;4(12):1795-8. doi: 10.2217/imt.12.126.

DOI:10.2217/imt.12.126
PMID:23240746
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4020625/
Abstract

Evaluation of: Chiba S, Baghdadi M, Akiba H et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13, 832-842 (2012). The identification of TIM-3 expression on tumor-associated dendritic cells (TADCs) provides insight into another aspect of tumor-mediated immunosuppression. The role of TIM-3 has been well characterized on tumor-infiltrating T cells; however, its role on TADCs was not previously known. The current paper demonstrated that TIM-3 was predominantly expressed by TADCs and its interaction with the nuclear protein HMGB1 suppressed nucleic acid-mediated activation of an effective antitumor immune response. The authors were able to show that TIM-3 interaction with HMGB1 prevented the localization of nucleic acids into endosomal vesicles. Furthermore, chemotherapy was found to be more effective in anti-TIM-3 monoclonal antibody-treated mice or mice depleted of all DCs, which indicated that a significant role is played by TADCs in inhibiting tumor regression. Taken together, these findings identify TIM-3 as a potential target for inducing antitumor immunity in conjunction with DNA vaccines and/or immunogenic chemotherapy in clinical settings.

摘要

评价

千葉 S、Baghdadi M、赤﨑 H 等人。肿瘤浸润树突状细胞(TADCs)通过 TIM-3 受体与警报素 HMGB1 的相互作用抑制核酸介导的固有免疫反应。Nat. Immunol. 13, 832-842 (2012)。在肿瘤相关树突状细胞(TADCs)上表达 TIM-3 的鉴定为肿瘤介导的免疫抑制提供了另一个方面的见解。TIM-3 在上的作用肿瘤浸润 T 细胞已有很好的描述;然而,其在 TADCs 上的作用以前并不清楚。目前的论文表明,TIM-3 主要由 TADCs 表达,其与核蛋白 HMGB1 的相互作用抑制了核酸介导的有效抗肿瘤免疫反应的激活。作者能够表明 TIM-3 与 HMGB1 的相互作用阻止了核酸进入内体小泡的定位。此外,发现化疗在抗 TIM-3 单克隆抗体治疗的小鼠或耗尽所有树突状细胞的小鼠中更有效,这表明 TADCs 在抑制肿瘤消退方面发挥了重要作用。总之,这些发现确定 TIM-3 作为与 DNA 疫苗和/或免疫原性化疗联合诱导抗肿瘤免疫的潜在靶点的临床环境。